BR112015030953A8 - compostos de piridina fundidos de heterociclo de cinco membros, método de produzir os mesmos, e uso dos mesmos - Google Patents

compostos de piridina fundidos de heterociclo de cinco membros, método de produzir os mesmos, e uso dos mesmos

Info

Publication number
BR112015030953A8
BR112015030953A8 BR112015030953A BR112015030953A BR112015030953A8 BR 112015030953 A8 BR112015030953 A8 BR 112015030953A8 BR 112015030953 A BR112015030953 A BR 112015030953A BR 112015030953 A BR112015030953 A BR 112015030953A BR 112015030953 A8 BR112015030953 A8 BR 112015030953A8
Authority
BR
Brazil
Prior art keywords
producing
fused
pyridine compounds
membered heterocycle
compounds
Prior art date
Application number
BR112015030953A
Other languages
English (en)
Other versions
BR112015030953B1 (pt
Inventor
Xiong Bing
Chen Danqi
Ding Jian
Ai Jing
Shen Jingkang
Ma Lanping
Geng Meiyu
Meng Tao
Peng Xia
Wang Xin
Ji Yinchun
Ma Yuchi
Chen Yuelei
Original Assignee
Shanghai Green Valley Pharmaceutical Co Ltd
Shanghai Greenvalley Pharmaceutical Co Ltd
Shanghai Inst Materia Medica Cas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Green Valley Pharmaceutical Co Ltd, Shanghai Greenvalley Pharmaceutical Co Ltd, Shanghai Inst Materia Medica Cas filed Critical Shanghai Green Valley Pharmaceutical Co Ltd
Publication of BR112015030953A8 publication Critical patent/BR112015030953A8/pt
Publication of BR112015030953B1 publication Critical patent/BR112015030953B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

resumo patente de invenção: "compostos de piridina fundidos de heterociclo de cinco membros, método de produzir os mesmos, e uso dos mesmos". esta invenção refere-se a uma classe de compostos de piridina fundidos de heterociclo de 5 membros como mostrado abaixo na fórmula (x), sais farmaceuticamente aceitáveis ou solvatos farmaceuticamente aceitáveis dos mesmos, um método de produzir a mesma, composições farmacêuticas contendo o composto, e uso dos compostos na preparação de medicamento para prevenir e/ou tratar doenças e tumores associados com proteína tirosina cinase anormal.
BR112015030953-4A 2013-06-19 2014-06-18 Piridina fundidas de heterociclo de cinco membros, seus usos, e composição farmacêutica BR112015030953B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310245354.8A CN104230922B (zh) 2013-06-19 2013-06-19 一类五元杂环并吡啶类化合物及其制备方法和用途
PCT/CN2014/000600 WO2014201857A1 (zh) 2013-06-19 2014-06-18 一类五元杂环并吡啶类化合物及其制备方法和用途

Publications (2)

Publication Number Publication Date
BR112015030953A8 true BR112015030953A8 (pt) 2018-01-23
BR112015030953B1 BR112015030953B1 (pt) 2022-03-29

Family

ID=52103891

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015030953-4A BR112015030953B1 (pt) 2013-06-19 2014-06-18 Piridina fundidas de heterociclo de cinco membros, seus usos, e composição farmacêutica

Country Status (14)

Country Link
US (1) US9988381B2 (pt)
EP (1) EP3012259B1 (pt)
JP (1) JP6594862B2 (pt)
KR (1) KR102289681B1 (pt)
CN (1) CN104230922B (pt)
AU (1) AU2014284013B2 (pt)
BR (1) BR112015030953B1 (pt)
CA (1) CA2908824C (pt)
DK (1) DK3012259T3 (pt)
ES (1) ES2802101T3 (pt)
PT (1) PT3012259T (pt)
RU (1) RU2668074C2 (pt)
SG (1) SG11201509511QA (pt)
WO (1) WO2014201857A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
WO2023078265A1 (zh) 2021-11-05 2023-05-11 上海海和药物研究开发股份有限公司 一种固体分散体、其制备方法及包含其的固体制剂
WO2023078408A1 (zh) * 2021-11-05 2023-05-11 上海海和药物研究开发股份有限公司 含met受体酪氨酸激酶抑制剂的药物组合及应用
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
EP1592690A1 (en) * 2003-02-14 2005-11-09 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
WO2004076450A1 (en) * 2003-02-27 2004-09-10 J. Uriach Y Compañia S.A. Pyrazolopyridine derivates
AU2007217040A1 (en) * 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-HT6 receptor affinity
EP2193130A1 (en) * 2007-09-06 2010-06-09 Array Biopharma, Inc. Pyrazolo-pyridines as tyrosine kinase inhibitors
DK3050874T3 (en) 2008-11-14 2019-04-01 Merial Inc ENANTIOMERALLY ENRICHED ARYLOAZOL-2-YL-CYANOETHYLAMINO ANTIPARASITARY COMPOUNDS
KR101023580B1 (ko) 2010-07-15 2011-03-21 전병수 승강기 와이어로프 장력 자동 균등화 장치
ES2546465T3 (es) 2010-10-29 2015-09-23 Pfizer Inc Inhibidores de N1/N2-lactama acetil-CoA carboxilasa
MX367341B (es) * 2012-05-08 2019-08-14 Merck Sharp & Dohme Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
US20140303121A1 (en) * 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
DK2970265T3 (en) * 2013-03-15 2018-10-01 Plexxikon Inc HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
MY182908A (en) * 2014-01-14 2021-02-05 Millennium Pharm Inc Heteroaryls and uses thereof

Also Published As

Publication number Publication date
US9988381B2 (en) 2018-06-05
AU2014284013B2 (en) 2018-04-05
EP3012259B1 (en) 2020-06-03
PT3012259T (pt) 2020-07-03
EP3012259A4 (en) 2016-11-23
RU2016101983A (ru) 2017-07-24
KR102289681B1 (ko) 2021-08-17
WO2014201857A1 (zh) 2014-12-24
DK3012259T3 (da) 2020-06-22
CN104230922B (zh) 2016-12-28
RU2668074C2 (ru) 2018-09-26
JP6594862B2 (ja) 2019-10-23
CA2908824C (en) 2021-05-25
EP3012259A1 (en) 2016-04-27
CA2908824A1 (en) 2014-12-24
AU2014284013A1 (en) 2016-02-11
BR112015030953B1 (pt) 2022-03-29
ES2802101T3 (es) 2021-01-15
SG11201509511QA (en) 2016-01-28
JP2016521757A (ja) 2016-07-25
US20160137640A1 (en) 2016-05-19
KR20160032003A (ko) 2016-03-23
CN104230922A (zh) 2014-12-24

Similar Documents

Publication Publication Date Title
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
EA201890001A1 (ru) Замещенные гетероциклические производные как ингибиторы циклинзависимой киназы (cdk)
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
BR112015023412A8 (pt) 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante, sua composição farmacêutica e seu uso.
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015001419A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
EA201690752A1 (ru) Ингибиторы g12c kras
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
BR112016003229A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
BR112015029455A8 (pt) compostos químicos, uso, métodos e composições para prevenção ou tratamento de câncer
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
BR112013014184A2 (pt) compostos de triazina [1,2,4] triazolo [4,3-b][1,2,4], método de preparo e seu uso
EA201591195A1 (ru) Новые хинолоновые производные
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
BR112014031091A2 (pt) Derivados de piperidina para agonista de gpr119
EA201690888A1 (ru) Новые гетероциклические соединения
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
BR112015029353A2 (pt) derivados de pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
PH12016502353A1 (en) Pharmaceutical composition
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
TW201613577A (en) Pharmaceutical combinations
BR112014006223A8 (pt) 3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACAD

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/06/2014, OBSERVADAS AS CONDICOES LEGAIS.